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Abstract: Bovine alphaherpesvirus 1 is ubiquitous in cattle populations and is associated with several
clinical syndromes, including respiratory disease, genital disease, infertility and abortions. Control of
the virus in many parts of the world is achieved primarily through vaccination with either inactivated
or live modified viral vaccines. The objective of this study was to evaluate the performance of four
commercially available BoHV-1 vaccines commonly used in Central and South America. Animals
were divided into eight groups and vaccinated on days 0 and 30. Groups 1 to 4 received two doses of
four different BoHV-1 commercial vaccines (named A to D). Groups 5 and 6 received vaccine D plus a
vaccine for either Clostridial or Food-and-Mouth-Disease (FMD), respectively. Group 7 received one
dose of two different brands of reproductive vaccines. Serum samples were collected from all animals
on days 0, 30 and 60 to evaluate neutralizing and isotype-specific (IgG1 and IgG2) antibodies. Of the
four commercial vaccines evaluated, only vaccine A induced neutralizing antibodies to titers ≥ 1:8
in 13/15 (86%) of the animals 60 days post-vaccination. Levels of IgG2 antibody increased in all
groups, except for group 2 after the first dose of vaccine B. These results show that only vaccine
A induced significant and detectable levels of BoHV-1-neutralizing antibodies. The combination
of vaccine D with Clostridial or FMD vaccines did not affect neutralizing antibody responses to
BoHV-1. The antibody responses of three of the four commercial vaccines analyzed here were
lower than admissible by vaccine A. These results may be from vaccination failure, but means to
identify the immune signatures predictive of clinical protection against BoHV-1 in cattle should also
be considered.
Keywords: BoHV-1; BoHV-1 vaccines in a field herd; Clostridial; FMD
1. Introduction
Bovine alphaherpesvirus 1 (BoHV-1) produces a wide variety of clinical manifestations,
including infectious bovine rhinotracheitis (IBR), infectious pustular vulvovaginitis and
balanoposthitis (IPV and IPB), infertility, abortion and systemic infection in newborn calves,
collectively causing substantive economic losses for cattle production chains worldwide.
BoHV-1 isolates are taxonomically divided into three different genotypes and subgenotypes,
based on their antigenic and genomic characteristics, named BoHV-1.1, BoHV-1.2a and
BoVH-1.2b [1,2].
Following infection, BoHV-1 (like other herpesviruses) establishes latent infections
in neuronal ganglia [3,4]. During latency, the virus remains in a non-replicative state
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in the form of episomes in the nuclei of infected cells. Upon reactivation, infectious
virions can then be shed and become a source of infection to other animals. Reactivation
can be experimentally induced by several stimuli, such as transport, parturition and
administration of glucocorticoids [5]. This peculiarity allows the virus to go undetected
and thus persist in herds, ensuring perpetuation of the virus [6].
The infection is widely distributed thought the world, with large differences in preva-
lence between countries. It is present in nearly all the countries of the Americas, Australia,
New Zealand and some countries of Europe, Asia and Africa. In Uruguay, the disease
is highly prevalent [7]. When BoHV-1-infected bulls are introduced into a herd, it has a
negative impact on reproductive performance from low conception rate to abortions [8].
Vaccination for BoHV-1 is thought to minimize reproductive losses and prevent clinical
signs in cattle, such as respiratory symptoms and conjunctivitis. A recently published
meta-analysis shows that the BoHV-1 vaccine is associated with a 60% decrease in the
risk of bovine abortion [9]. Inactivated BoHV-1 vaccines can be safely used in pregnant
animals and so are widely used in breeding herds with other vaccines for pathogens, such
as Bovine Viral Diarrhea (BVD), Leptospira spp and Campylobacter fetus. Other immunogens,
such as Clostridial antigens, and Foot and Mouth Disease Virus (FMDV) are often applied
simultaneously with vaccines against infectious diseases that affect reproduction in cattle.
However, it is not clear whether such immunization protocols interfere with the immune
response against BoHV-1.
Primary BoHV-1 infection induces strong humoral and cell-mediated immune re-
sponses in cattle, as would be expected under normal conditions [10,11]. The serum
neutralization (SN) test used to quantify BoHV-1 neutralizing antibodies in sera of cat-
tle is recommended by the World Organization for Animal Health (OIE). SN has been
used extensively to evaluate vaccines [11–14], although there is a difference in the titers
obtained according to the sample used [15]. Moreover, it has been shown that the efficacy
of the immune response against BoHV-1 depends on increased Th1-type cell-mediated
responses [16]. The measurement of subclass-specific (IgG1 and IgG2) levels in serum
allows an indirect estimate of the profile of the cellular immune response induced after
vaccination. Thus, elevated IgG1 levels are related to a Th2 response profile, while high
IgG2 levels are associated with a Th1 profile [17,18].
The aim of this study was to evaluate the effectiveness of four inactivated BoHV-1
vaccines commonly available in Uruguay by measuring levels of neutralizing antibodies
and specific immunoglobulin subclasses induced by the vaccines. Responses were also
evaluated when Clostridial or Foot and Mouth Disease (FMD) vaccines were applied
simultaneously.
2. Materials and Methods
2.1. Animals
The experiment was carried out in a livestock farm located in the Lavalleja Department,
Uruguay. From a herd with approximately 1000 Herefords, 120 heifers seronegative against
BoHV-1 were selected and divided into eight groups of 15 animals each. The experimental
protocols for the cattle studies performed in this paper were approved by Animal Use
Ethics Commission (CEUA) from the Universidad de la República Oriental del Uruguay
(approval number CEUAFVET-972, Exp. 111900-001057-19).
2.2. Vaccination Protocols
The animals were divided into 8 groups of 15 animals each. Groups 1 to 4 received two
doses (day 0 and day 30) of different commercial BoHV-1 vaccines. Groups 5 and 6 received
a BoHV-1 vaccine in combination with a vaccine for Clostridial (double dose—days 0 and
30) or FMD (single dose—day 0) and group 7 received different brands of reproductive
vaccine in each dose. The control group (group 8) was not vaccinated and they were kept
in the same herd as the vaccinated animals. (Table 1).
Vaccines 2021, 9, 408 3 of 11






5 D + Clostridial vaccine
6 D + FMD vaccine
7 A (1st dose) + D (2nd dose)
Control Non-vaccinated
FMD: Foot and Mouth Disease.
Blood was collected by coccygeal venipuncture on days 0, 30 and 60 from all animals
and sera were stored at −20 ◦C until processing.
2.3. Vaccines
Six different commercial vaccines with the following antigens were used:
1. Vaccine A: inactivated suspension of BoHV-1, bovine viral diarrhea virus (BVDV)-1,
Campylobacter fetus, Histophilus somni and Leptospira spp in aluminum hydroxide adjuvant.
2. Vaccine B: inactivated suspension of BoHV-1, BoHV-5; BVDV-1, BVDV-2; Leptospira
spp and Campylobacter fetus in aluminum hydroxide adjuvant.
3. Vaccine C: inactivated BoHV-1, BVDV-1, Campylobacter fetus, Leptospira spp and
Histophilus somni in aluminum hydroxide adjuvant.
4. Vaccine D: inactivated suspension of BoHV-1, BoHV-5, BVDV-1, BVDV-2, Leptospira
spp and Campylobacter fetus in oil—adjuvant.
5. Clostridial vaccine: Bacterin-toxoid combined with a water-soluble adjuvant con-
taining Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum,
Clostridium novyi, Clostridium sordellii, Clostridium perfringens types B and C and
Clostridium perfringens type D.
6. FMD vaccine: Oil emulsion vaccine containing inactivated Foot and Mouth Disease
Virus types O1 Campos and A24 Cruzeiro.
For informational purposes, the reproductive vaccines used were (listed in alphabeti-
cal order): BIOABORTOGEN® H—Biogénesis—Bagó, Buenos Aires, Argentina; BOVISAN
TOTAL Se®—Virbac, Montevideo, Uruguay; TRANSVAC®—Merial, Buenos Aires, Ar-
gentina; and VAC-SULES REPRODUCTIVA FORTE®—Microsules, Montevideo, Uruguay.
The order of appearance of the marks does not necessarily coincide with the description
A to D.
2.4. Serum Neutralization (SN) Test
Serum samples were submitted to a serum neutralization (SN) test for detection of
antibodies to BoHV-1, according to the OIE protocol [19]. Briefly, 50 µL of a two-fold
dilution of each serum was mixed with an equal volume of a suspension containing
100 TCID50 (50% tissue culture infectious dose) of BoHV-1 Los Angeles strain (LA—BoHV-
1.1). After 24 h incubation at 37 ◦C, 50 µL of a cell suspension (3 × 104 cells) was added
to wells and plates incubated at 37 ◦C in a 5% CO2 incubator. Plates were examined for
cytopathic effect (CPE) using a light microscope daily for five days. Antibody titers were
expressed as the reciprocal of the highest serum dilution that prevented the induction
of CPE after 5 days of incubation. SN antibody titers ≥ 1:8 was used as the cut-off for
protection [20].
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2.5. Indirect ELISA
For the quantification of BoHV-1-specific total IgG, IgG1 and IgG2, three indirect
ELISAs were developed. A stock ELISA antigen was prepared on MDBK cells infected
with BoHV-1 LA strain at a multiplicity of infection (MOI) between 0.1 and 1 and further
treated with 0.2% N-octyl-glucopyranoside (OGP) following previously described meth-
ods [11]. Class and subclass-specific peroxidase conjugates (anti-bovine IgG, IgG1 and
IgG2 antibodies) were purchased commercially and employed following the manufacturers’
instructions (Jackson Immunoresearch Laboratories INC, West Grove, PA, USA). The plates
were coated with a 1:1500 dilution of the antigen in bicarbonate buffer overnight at 4 ◦C.
After the adsorption of the antigen, plates were washed once with 100 µL of PBST-20 (0.5%
Tween 20 in 83.3 mM KH2PO4, 66 mM Na2HPO4, 14.5 mM NaCl), filled with another
100 µL of PBST-20 and allowed to stand at room temperature for 1 h. For testing, sera were
diluted 1:2 in PBST-20 and added to wells in duplicate. After 1 h incubation at 37 ◦C, plates
were washed three times with PBST-20. Class or subclass-specific peroxidase conjugates
(diluted in PBS as previously titrated) were then added to wells and the plates were again
incubated for 1 h at 37 ◦C. After another series of washings with PBST-20, 100 µL of the
substrate ortho-phenylenediamine (OPD; Sigma, Darmstadt, Germany) with 0.03% H2O2
were added to plates [11]. After 30-min incubation at room temperature, the optical density
(OD) was determined at 405 nm in a Multiskan (Titertek, Waltham, Massachusetts, EUA)
ELISA reader.
2.6. Statistical Analysis
Fisher’s exact test was used in the analysis of contingency tables and a Student’s t test
was conducted to compare the means between groups for the different isotypes considering
the time factor (GraphPad Prism 6). The significance level was p < 0.05.
3. Results
The results of the neutralizing antibody titrations of each experimental group are
shown in Table 2 and a supplemental file is provided with the complete results. Only
vaccine A induced antibody titers ≥1:8 in most animals (86%) at day 60.
Table 2. Neutralization antibodies for BoHV-1 at 30 and 60 days post-vaccination (dpv) in cattle immunized with four
commercial vaccines.
Groups Vaccines Number of Animals
Reagents
30 dpv 60 dpv








2 B 15 0 * 0 b
3 C 15 1 *#1(8)
1 b
#1(8)











6 D + FMD 15 1 *#1(8)
1 *,b
#1(8)
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Table 2. Cont.
Groups Vaccines Number of Animals
Reagents
30 dpv 60 dpv





Control Non-vaccinated 15 0 * 0 *,b
* Number of reactive animals; # Number of animals and neutralizing antibody titers detected (in parentheses). All animals were seronegative
for SN test at day 0. The different letters (a,b and c) show significant differences (p < 0.05).
The indirect ELISA for total antibodies (p < 0.05) relative to IgG1 and IgG2 against
BoHV-1 demonstrated that commercial vaccine A used in group 1 induced higher titers of
antibodies (p < 0.05) compared to the groups that received vaccines C and D, while vaccine
B did not induce detectable antibodies in any of the samples collected (Figure 1A).
Figure 1. Antibodies to BoHV-1 evaluated by ELISA in sera of cattle immunized with four commercial BoHV-1 vaccines.
Group 1 = vaccine A; group 2 = vaccine B; group 3 = vaccine C; group 4 = vaccine D; and Control group (not vaccinated).
Mean titers ± standard errors (SEM) are depicted. Letters (a, b and c) highlight significant differences (p < 0.05) between
groups. A: Total IgG antibodies. B: IgG1 subclass antibodies. C: IgG2 subclass antibodies.
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The subclass-specific antibody revealed a low IgG1 response in all groups (Figure 1B),
while IgG2 showed a significant increase in groups 1, 3 and 4 on day 60 post-immunization
(Figure 1C).
Additionally, the antibody response against BoHV-1 was evaluated when other vac-
cines were given simultaneously (Clostridial—group 5 or FMD—group 6). At day 30, the
animals immunized with BoHV-1 + Clostridial or BoHV-1 + FMD produced a significantly
lower antibody response than the group immunized only with BoHV-1. However, on day
60, this difference had disappeared (Figure 2A). For the antibody subclasses analyzed,
a weak IgG1 response was evident in all groups at 30 and 60 days after immunization
(Figure 2B), while IgG2 showed a significant increase in vaccinated groups 4, 5 and 6 on
day 60 of the experiment (Figure 2C).
Figure 2. Antibodies to BoHV-1 evaluated by ELISA in sera of cattle immunized with commercial reproductive vaccines
applied simultaneously with Clostridial or FMD vaccines. Group 4 = vaccine D; group 5 = vaccine D + Clostridial vaccine;
group 6 = vaccine D + FMD vaccine and Control group (not vaccinated). Mean titers ± standard errors (SEM) are shown.
Letters (a, b and c) highlight significant differences (p < 0.05) between groups. A: Total IgG antibodies. B: IgG1 subclass
antibodies. C: IgG2 subclass antibodies.
The antibody titer showed that on day 60, the titers were significantly different when the
vaccine brand was changed between the first and second dose (group 7—vaccine D on day 0
and vaccine A on day 30). At day 60, vaccine A induced the highest antibody titers, while
vaccine D induced the lowest antibody titers (p < 0.05). When the vaccine brand between
both immunizations was changed (group 7), the response at day 60, an intermediate response
between the response of vaccine A and D (Figure 3A), was achieved. For the antibody
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subclasses analyzed, IgG1 level was not different between the groups (Figure 3B), while the
IgG2 values at day 60 were significantly higher in group 7 (Figure 3C).
Figure 3. Antibody titers evaluated by ELISA in bovine sera immunized on day 0 with vaccine A and day 30 with vaccine
D. Group 1 = vaccine A; group 4 = vaccine D; group 7 = vaccine A + D; and Control group = not vaccinated. Mean
titers ± standard errors (SEM) are shown. Letters (a, b, c and d) highlight significant differences (p < 0.05) between groups.
A: Total IgG antibodies. B: IgG1 subclass antibodies. C: IgG2 subclass antibodies.
4. Discussion
Uruguay has one of the highest beef and milk production volumes per capita in
the world, as well as being one of the largest consumers of beef per inhabitant. Thus,
livestock production is not only of economic importance but also is a major part of the
diet of the country’s population. As such, animal health is a substantial concern for the
production chain in the management system regularly employed in Uruguay’s cattle
farms. At the production level, there is discussion about the efficacy and durability of the
response obtained with the available reproductive vaccines, despite the ample number
of recognized national and international vaccines available. Here, different protocols
have been developed to analyze the antibody response against BoHV-1 using multivalent
commercial vaccines in a field herd. It is necessary to clarify that none of the BoHV-1
vaccines tested in this study were monovalent, although the objective here was to evaluate
the response of these multivalent vaccines against BoHV-1. In addition, the responses to
the Clostridial and FMDV in this study have not been evaluated.
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At the international level, vaccines that protect against BoHV-1 are expected to gener-
ate at least a neutralizing antibody titer of ≥1:8 [20], although it cannot be ruled out that
immunization may still have a protective effect in animals with medium or low antibody
titers. It is necessary to clearly define the immune signatures predictive of clinical protec-
tion against BoHV-1 in cattle. Variation in responses observed among vaccines may be
associated with the lack of specific parameters outlined for their production, inadequate
quality control and/or use of inefficient adjuvants. Inappropriate handling and storage
are also factors that negatively affect the immunogenicity of vaccines [21]. Here, we use
registered vaccines that have been commercially available for many years. Two of these
vaccines are manufactured abroad, while the other two are manufactured in Uruguay
and exported to various countries. Presumably, the commercial vaccines have undergone
rigorous quality controls; however, 3 out of the 4 vaccines evaluated here did not generate
satisfactory levels of antibodies to ensure that they would protect against infection in the
field with BoHV-1, or we must assume that the protective response is not based exclusively
on the production of detectable levels of neutralizing antibodies.
The humoral responses of the vaccines differed from previous studies which detected
higher levels of neutralization antibodies against BoHV-1 by SN test [20–22]. In particular,
Anziliero et al. [20] found a level of protection against BoHV-1 between 80 and 100% in eight
commercial vaccines tested in Brazil. In these studies, the differences found may have been
due to the brands of vaccines tested, the control strain used (they used the Cooper strain
and we used the Los Angeles strain), as well as the viral incubation neutralization time,
which, in our case, was 24 h [19], while they used two hours. Another study showed that
SN sensitivity varied greatly depending on the challenge virus used in the test, particularly
when results against each virus were considered individually [15]. In addition, there is
a difference between the vaccine strains (we have to say which strain the vaccines use)
and the Los Angeles samples used in the SN test, which can also influence the detected
antibody titer. Thus, the comparison of results with previous studies has to be done
with reservations.
Recently, other researchers have analyzed the serological response against BoHV-1
by comparing live vaccines (MLV) and inactivated vaccines [23,24]. The best protective
response was observed in heifers vaccinated with live modified thermosensitive virus [24].
However, in a meta-analysis where the prevention of abortion in cattle following vaccina-
tion against BoHV-1 was reviewed, it was found that both MLV and inactivated vaccines
decrease abortion risk. Regardless of potential risk, the overall effect of MLV vaccines
was a protective effect against abortion [9]. In Uruguay, live vaccines are prohibited and
therefore their use in our experiment was not possible.
Additionally, we tested the immunogenicity of vaccine D applied simultaneously with
a Clostridial vaccine (Group 5), as well as when applied with an FMD vaccine (Group 6).
The practice of applying two or more vaccines simultaneously is widely used in Uruguay
and in various countries of the region to optimize the handling of animals. However, there
is a lack of field experiments that demonstrate that this practice does not affect the quality
of the expected immune response for each immunogen used. Here, it did not generate
acceptable levels of protection against BoHV-1 (Table 2), though a significant difference
was observed in the IgG titers at day 30 in both groups (5 and 6) compared to the control.
This shows that the simultaneous immunization could have affected the initial activation
of the immune system (primary response), but then this difference disappeared at day
60. This allows us to assume then that there would be no interference with the response
against BoHV-1, at least with the titers of generated antibodies. Despite this, the quality and
duration of the humoral and cellular immune response to vaccination should be studied in
future experiments.
It is not uncommon for farmers to use a different brand of vaccine for the second
dose of the vaccine. Anecdotally, this practice is associated with a higher-quality immune
response than applying the same brand in both immunizations. Here, in group 7, we
applied vaccine A in the first dose and vaccine D in the second dose. The levels of
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protection determined by the neutralizing antibody titers for vaccine A and D were 86%
and 20%, respectively, while the combination of brands A + D (group 7) achieved protective
titers in 33% of animals (Table 1). Therefore, it was found that the response of vaccine
A was affected by changing the brand, while the response of vaccine D was favored in
that group.
Most immune responses associated with vaccination are controlled by specific T cells
of a CD4+ helper phenotype, which mediate the generation of effector antibodies, cytotoxic
T lymphocytes (CTLs), or the activation of innate immune effector cells [25]. Although T
helper cells play a central role in the induction of a protective immune response against
infections from viral pathogens, Th2 cells producing interleukin (IL)-4, IL-13 and IL-5 can
be detrimental in an infection. Several murine studies firmly established that IL-4 regulates
B cells for the secretion of IgG1 antibodies, whereas interferon-γ stimulates the expression
of IgG2a antibodies, rendering either isotype an indicator of the underlying Th2 or Th1
response in mice [26]. It has also been shown in cattle that IgG1 expression is positively
regulated by IL-4, and IgG2 expression is positively regulated by IFN-gamma [17]. In
examining the results of the in-house ELISA employed here, high levels of IgG2 were
detected in sera of animals vaccinated with all four vaccines and combinations of vaccines,
except vaccine B, where no antibody levels were detected. This significant increase in IgG2
would suggest that a Th1 response profile was activated after vaccination. In addition, we
had previously found an IgG2 response in animals naturally infected with BoHV-1 [27],
as well as animals vaccinated against BoHV-1; the immune response profile is Th1 with a
predominance of IgG2.
In conclusion, our study showed that the four commercial BoHV-1 multivalent vac-
cines tested produced different antibody levels in cattle after the complete vaccination
protocol. Only one vaccine fulfilled the minimum requirements of immunogenicity, confer-
ring adequate neutralizing antibodies in the vaccinated animals. When we evaluate the
IgG response, high IgG2 titers were found for all vaccines that had a detectable serological
response, indicating a Th1 response profile that is adequate for antiviral response. Taken
together, these results demonstrate that the level of neutralizing antibodies alone may not
be an adequate parameter for determining protection against BoHV-1. A virus challenge
was not carried out in this study and would be an appropriate follow-up study to this work.
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